



## Curriculum Vitae

Personal information **Sayeh Ahrabi**

### Work experience

---

1. Employer: Norwegian Medicines Agency
  - Start date: 012017
  - End date:
  - Position: Strategic director, Medicines supply chain and medical devices
  - Activities:
  - Country: Norway
2. Employer: Norwegian Medicines Agency
  - Start date: 012010
  - End date: 012017
  - Position: Head of section, Pharmaceutical evaluation
  - Activities:
  - Country: Norway
3. Employer: Clavis Pharma
  - Start date: 012004
  - End date: 122009
  - Position: Director Pharmaceutical R&D
  - Activities: Formulation development and manufacture for preclinical and clinical studies
  - Country: Norway
4. Employer: Weifa
  - Start date: 022003
  - End date: 122003
  - Position: Head of formulation development
  - Activities: Formulation development (mainly tablets), upscaling and technical transfer to production facilities
  - Country: Norway
5. Employer: Alpharma
  - Start date: 012001
  - End date: 012003
  - Position: Pharmaceutical advisor
  - Activities: Process development for tablets and semisolids, scale up and technical transfer from R&D to production facilities
  - Country: Norway
6. Employer: School of Pharmacy, University of Oslo
  - Start date: 082000
  - End date: 122000
  - Position: Senior lecturer
  - Activities: Develop a new practical course in pharmaceutical technology as well as planning the practical exam
  - Country: Norway

### Education and training

---

1. Subject: University of Oslo, School of Pharmacy
  - Start date: 011994
  - End date: 121999
  - Qualification: PhD (Dr.scient.)
  - Organisation: Pharmaceutical sciences and technology
  - Country: Norway
2. Subject: University of Oslo, School of Pharmacy
  - Start date: 081992
  - End date: 121993
  - Qualification: MScPharm
  - Organisation: Supplementary courses to the Pharmacy education that was started in Iran, and thesis within pharmaceutical sciences
  - Country: Norway
3. Subject: Centre for Entrepreneurship, University of Oslo
  - Start date: 082009
  - End date: 052012
  - Qualification: MSc Innovation and Entrepreneurship
  - Organisation: Innovation management and entrepreneurship
  - Country: Norway

### Additional information

---

#### Publications

Ahrabi SF, Heinämäki, J, Sande SA and Graffner, C. (2000). Influence of neutron activation factors on matrix tablets aimed for site specific delivery to colon. Eur. J. Pharm. Sci., 10, 225\_235. Ahrabi SF, Madsen G, Dyrstad K, Sande SA and Graffner C. (2000). Development of pectin matrix tablets for colonic delivery of model drug ropivacaine. Eur. J. Pharm. Sci., 10, 43\_52. Ahrabi SF (1999). Radiolabelling of potential colonic delivery systems by neutron activation. An evaluation based on physicochemical properties of the excipients and formulations. Thesis for the

degree of Dr.Scient., University of Oslo. Ahrabi SF, Sande SA, Waaler T and Graffner C. (1999). Effects of thermal neutron irradiation on some potential excipients for colonic delivery systems. *Drug Dev. Ind. Pharm.*, 25, 453\_462. Ahrabi SF, Sande SA, Waaler T and Graffner C. Influence of neutron activation factors on the physicochemical properties of suppositories and their excipients. *Eur. J. Pharm. Sci.*, 8, 193\_201. Ahrabi SF. (1993). Stability of liposomes: oxidation of phospholipids and its relation to zeta potential variations. Thesis for the degree of Cand. Pharm., University of Oslo, Norway. Ahrabi SF, Hagen S, Myhren F. (2008). CP\_4126 oral product development: In\_silico absorption prediction, oral metabolic stability and preliminary bioavailability study in beagle dogs. Poster presentation at American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, November 2008, Atlanta, GA, USA.

#### Projects

Patents on Elacytarabine and CP\_4126 oral/intravenous formulations for Clavis Pharma. The development of both products were stopped due to phase III failure.

#### Memberships

#### Other Relevant Information